BioMarin Pharmaceutical Inc. (BMRN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in San Rafael, CA, United States. Der aktuelle CEO ist Alexander Hardy.
BMRN hat IPO-Datum 1999-07-26, 3,040 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $10.67B.
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes therapies for rare and life-threatening genetic and metabolic diseases. The company's approved commercial products include Vimizim and Naglazyme for mucopolysaccharidosis disorders, Kuvan and Palynziq for phenylketonuria, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for lysosomal storage disease. BioMarin's pipeline includes late-stage gene therapy candidates such as valoctocogene roxaparvovec for hemophilia A and BMN 307 for phenylketonuria, along with BMN 255 in development for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and pharmaceutical wholesalers across the United States, Europe, Latin America, and international markets, while maintaining strategic partnerships with leading biotechnology firms.
